Deletions and LoF mutations in TBX4 cause a variety of developmental lung disorders [199] and have been identified as a prominent risk factor in small patella syndrome (SPS) [200], childhood-onset PAH [108] and more recently, persistent pulmonary hypertension in neonates [201]. Here, TBX4 is linked to pulmonary arterial hypertension.